Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S. https://t.co/Ke6Oy7u1rl ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect. Single-dose vials of Zepbound purchased through the Zepbound Self Pay Journey Program on LillyDirect will now cost $299 per month – down from $349 – for patients with a valid prescription.The 5-milligram dose will also be priced at $399 per month, down from $499. All other approved doses will cost $449 per mo ...

Welcome to Market Catalyst. I'm Julie Hyman. We're 30 minutes into the US trading day and here is what we're watching this hour. First off, stocks drop to kick off December trading. We're going to break down the market action heading into year end. Plus, we'll get the latest read on the economy with the ISM manufacturing data crossing the wire coming in and contracting once again. and we'll bring you the latest figures on holiday shopping as investors look for cues, clues, and cues on the health of the US c ...

PresentationMavic Cuevas Good morning and good afternoon. Welcome to our 12th Annual Social Impact and Sustainability Event. Before we start, I would like to quickly read our safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of so ...

 The United States and Britain announced a deal on Monday to secure zero tariffs on British pharmaceutical products and medical technology in return for Britain spending more on medicines and overhauling how it values drugs.Under the agreement, Britain will raise the net price it pays for new US medicines by 25%. In return, UK-made medicines, drug ingredients and medical technology will be exempt from Section 232 sectoral tariffs and any future Section 301 country tariffs.“The United States and the United K ...

Memo also reportedly mentions vaccines for flu and pneumonia. ...

Key Takeaways CORT's revenues are driven by Korlym, which posted $559.3M in nine-month sales in 2025, up 13.4% y/y.The company expects full-year 2025 revenues of $800M-$850M and sustained Korlym growth.Corcept filed NDAs for relacorilant in Cushing's and ovarian cancer, with FDA decisions due in 2025 and 2026.Corcept Therapeutics (CORT) has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism. Cur ...

Key Takeaways Amgen shares jumped almost 16% in a month on strong Q3 results and higher sales guidance.Growing demand for key drugs, new products and biosimilars is driving Amgen's revenue gains.Amgen's expanding pipeline, including MariTide, offers multiple upcoming catalysts.Amgen’s (AMGN) stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also raised its sales guidance for the ...

The FDA approval of LYMPHIR was based on data from Pivotal Study 302 (NCT01871727), which evaluated the efficacy and safety of LYMPHIR in patients with Stage I–III CTCL who had received at least one prior systemic treatment. The study demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden. Moreover, LYMPHIR demonstrated meaningful activity on severe pruritus (itchiness), a significant quality of life issue for CTCL patients. Media ...

Treasuries fell as US trading returned to normal after last week’s holiday, with a surge of new corporate bond supply to begin the last month of the year. Most Read from Bloomberg Yields accelerated higher during US morning — led by long-maturity tenors — after Merck & Co. slated an eight-part bond offering that includes 20-, 30- and 40-year tranches. Government bonds globally were already under pressure as Japan’s 10-year yield jumped to the highest level since 2008 on the prospect of a Bank of Japan in ...